




SECCIÓN 6 / SECTION 6
LEUCEMIAS LINFÓIDES: DESDE LA GENÉTICA AL TRATAMIENTO
LYMPHOID LEUKEMIAS: FROM GENETICS TO TREATMENT

- 11:00 **Notch signaling in normal and leukemic hematopoiesis**
Anna Bigas, PhD
Centro de Oncología Molecular, Institut de Recerca Oncològica, Barcelona, Spain
- 11:30 **Role of matrix metalloproteinase-9 in the pathogenesis of B-cell chronic lymphocytic leukemia**
Ángeles García-Pardo, PhD
Department of Immunology, Centro de Investigaciones Biológicas (CSIC), Madrid, Spain
- 12:00 **Risk adapted treatment of adult acute lymphoblastic leukemia**
José M. Ribera, MD
Hospital Universitari Gernas Trias i Pujol, Badalona, Spain
- 12:30 **Ceremonia de clausura / Closing Ceremony**



Simposio Internacional:
Nuevas fronteras en el diagnóstico y tratamiento de los tumores hematológicos
International Symposium:
New Frontiers in Hematological Malignancies



Pamplona,
16 –18 de Noviembre de 2011
Pamplona,
16th–18th of November of 2011



INFORMACIÓN GENERAL

GENERAL INFORMATION

SEDE / VENUE

Palacio Congreso Baluarte
Plaza Baluarte s/n
31002 Pamplona. España



COORDINADORES / COORDINATORS

Dr. Felipe Prósper

Clínica Universidad de Navarra. Pamplona.

Dr. José A. Martínez-Climent

Centro de Investigación Médica Aplicada. Pamplona

COMITÉ ORGANIZADOR / MANAGEMENT COMMITTEE

Dr. Pierre Brousset

Institut National de la Santé et de la Recherche Médicale. Toulouse

Dr. María J. Calasanz

Universidad de Navarra. Pamplona

Dr. Eric Delabesse

Institut National de la Santé et de la Recherche Médicale. Toulouse

Dr. Cyril Broccardo

Institut National de la Santé et de la Recherche Médicale. Toulouse

Dr. Xabier Agirre

Centro de Investigación Médica Aplicada. Pamplona

Dr. María D. Otero

Centro de Investigación Médica Aplicada. Pamplona

Dr. Andrew Solomon

Centro de Investigación Médica Aplicada. Pamplona

D. Elías Rodríguez Toral

Centro de Investigación Médica Aplicada. Pamplona

CONTACTO / CONTACT

Tif: +34948194700

asolomon@unav.es

PROGRAMA CIENTÍFICO

SCIENTIFIC PROGRAMME

16 DE NOVIEMBRE / 16th OF NOVEMBER

15:45 - 16:00 REGISTRO Y RECOGIDA DE DOCUMENTACIÓN / REGISTRATION AND CONGRESS DOCUMENTATION

16:00 - 16:30 BIENVENIDA / WELCOME

SECCIÓN 1 / SECTION 1

PAPEL DE CÉLULAS MADRES EN TUMORES HEMATOLÓGICOS

ROLE OF STEM CELLS IN HEMATOLOGICAL MALIGNANCIES

16:30 **New heterogeneity of the Leukemic Initiating Cells: implications for therapeutic intervention**

Dominique Bonnet, MD

London Research Institute, Lincoln's Inn Fields Laboratories, London, United Kingdom

17:00 **Targeting disease risk in AML mediated by Leukemic Stem Cells**

Ash Alizadeh, MD, PhD

Department of Oncology and Hematology, Stanford University School of Medicine, Stanford, California, USA

17:30 **Café / Coffee break**

18:00 **Reprogramming of hematopoietic stem cells into tumor cells by oncogenes: Implications in the development and treatment of hematological malignancies**

Isidro Sánchez-García, MD, PhD

Instituto de Biología Molecular y Celular del Cáncer, Centro de Investigación del Cáncer, CSIC/Universidad de Salamanca, Salamanca, Spain

18:30 **The hematopoietic stem cell niche**

David Scadden, MD

Massachusetts General Hospital, Harvard Stem Cell Institute, Harvard University, Boston, Massachusetts, USA

17 DE NOVIEMBRE / 17th OF NOVEMBER

SECCIÓN 2 / SECTION 2

BIOLOGÍA Y TERAPIA DE NEOPLASIAS MIELOIDES

BIOLOGY AND THERAPY OF MYELOID MALIGNANCIES

08:45 **Dissecting the molecular mechanism of arsenic-induced cures in APL**

Hughes de Thé, MD

Department of Molecular Pathology, Institut National de la Santé et de la Recherche Médicale, Paris, France

09:15 **Molecular genetics of myeloproliferative neoplasms**

Nicholas C.P. Cross, PhD

Wessex Regional Genetics Laboratory, Salisbury District Hospital, Salisbury, United Kingdom

09:45 **Identification of activated signaling pathways in leukemia**

Jan Cools, PhD

Department of Molecular and Developmental Genetics, VIB. Leuven, Belgium

10:15 **Café / Coffee break**

10:45 **Treatment of Acute Myeloid Leukemia based on target therapies**

Miguel A. Sanz, MD

Department of Hematology, Hospital Universitario La Fe, Valencia, Spain

11:15 **New prognostic factors in Acute Myeloid Leukemia**

Clara Bloomfield, MD

The Ohio State University, Columbus, Ohio, USA

SECTION 3 / SECTION 3

MIELOMA MÚLTIPLE Y OTRAS ENFERMEDADES LINFOPROLIFERATIVAS

MULTIPLE MYELOMA AND OTHER CHRONIC LYMPHOPROLIFERATIVE DISORDERS

12:00 **Targeting CDK4/6 in myeloma and MCL: Mechanism, Genomics and Therapy**

Selina Chen-Kiang, PhD

Department of Pathology and Immunology, Weill-Cornell Medical College; New York, USA

12:30 **New Therapies in patients with Multiple Myeloma**

Jesús San Miguel, MD

Department of Hematology, Hospital Clínico de Salamanca, Salamanca, Spain

15:30 **Almuerzo / Lunch**

SECCIÓN 4 / SECTION 4

NUEVAS PERSPECTIVAS EN LINFOMAS DE CÉLULAS-B: DESDE LAS MOLÉCULAS A LAS TERAPIAS DIRIGIDAS

NEW INSIGHTS IN B-CELL LYMPHOMAS: FROM MOLECULES TO DIRECTED THERAPIES

15:00 **Epigenetic modifications and cancer**

Manel Esteller, MD

Programa de Biología y Epigenética del Cáncer (PEBC), Instituto de Investigación Biomédica de Bellvitge (IDIBELL), Barcelona, España.

15:30 **Genome and Transcriptome Sequencing as a Discovery Tool in Lymphoid Malignancies**

Randy D. Gascoyne, MD, PhD

Department of Pathology, British Columbia Center Agency, Centre for Lymphoid Cancer, Vancouver, Canada

16:00 **Converging on the Achilles heel of lymphoma by functional and structural genomics**

Louis Staudt, MD, PhD

Metabolism Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland, USA

16:45 **Café / Coffee break**

17:15 **Transcription factor induced transdifferentiation as a therapeutic approach**

Thomas Graf, PhD

Centro de Regulación Genómica (CRG), Barcelona, Spain

17:45 **Prognostic biomarkers in B-cell lymphomas**

Izidore Lossos, MD

Division of Hematology and Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida, USA

18:15 **Lymphoma: Identifying markers for targeted therapy**

Miguel A. Piris, MD.

Department of Pathology and hematology, Hospital Universitat Marqués de Valdecilla, Santander, Spain

18 DE NOVIEMBRE / 18th OF NOVEMBER

SECCIÓN 5 / SECTION 5

MECANISMOS EPIGÉNICOS COMO DIANAS TERAPÉUTICAS POTENCIALES

EPIGENOMIC MECHANISMS AS POTENTIAL THERAPEUTIC TARGETS

08:45 **Regulation of alternative splicing in cancer**

Juan Valcárcel, PhD

Center for Genomic Regulation (CRG), Barcelona, Spain

09:15 **DNA Methylation in Lymphoid Neoplasms**

José I. Martín-Subero, PhD

Department of Anatomic Pathology, Pharmacology & Microbiology, University of Barcelona, Centre Esther Koplowitz, Barcelona, Spain

09:45 **Epigenetic gene regulation in acute leukemia**

Ari Melnick, MD

Division of Hematology/Oncology, Weill Cornell Medical College, New York, NY, USA

10:30 **Café / Coffee break**